Key result
Inhibiting miR-34a protects female mice with moderate DCM better than males, but fails in severe cases.
Why the study?
Whether inhibition of miR-34a protects the female heart was unknown, and its therapeutic potential in dilated cardiomyopathy and atrial fibrillation had not been assessed.
Does LNA-antimiR-34a improve cardiac function and morphology in male and female mouse models of dilated cardiomyopathy?
Population
Male and female mouse models of moderate DCM and severe DCM with AF
Comparison
LNA-antimiR-34a administration across sexes and disease models
Design
Preclinical animal study
Follow-up
6 weeks
Authors
Loading...
Sex-specific protection in moderate DCM should not guide therapy; leaves open hypothesis-generating role for miR-34a inhibition pending human studies.
Does LNA-antimiR-34a improve cardiac function and morphology in male and female mouse models of dilated cardiomyopathy?
Inhibition of miR-34a provides sex-specific protection in a mouse model of moderate dilated cardiomyopathy, being more effective in females, but shows no benefit in severe DCM with AF.
Bernardo et al. (2016) studied Dilated cardiomyopathy (DCM) and atrial fibrillation (AF). LNA-antimiR-34a was evaluated on Cardiac function and morphology. Inhibition of miR-34a using LNA-antimiR-34a provided more protection against cardiac dysfunction in female mice with moderate dilated cardiomyopathy than in males, with no benefit in severe DCM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: